Moscow: Scientists at Rosatom's Research Institute of Nuclear Materials (INM JSC) in Zarechny, Sverdlovsk Oblast, have pioneered a method to produce terbium-161, a medical isotope effective in cancer treatment.

This marks Russia's debut in manufacturing this vital isotope. Terbium-161, when used in radiopharmaceuticals, emits beta particles and Auger electrons, offering significant therapeutic benefits.

According to Dr. Andrey Stanzhevsky, Deputy Research Director at the A.M. Granov Russian Scientific Center, preclinical studies reveal that terbium-161 delivers 1.5 times higher doses than similar pharmaceuticals. This reduces the required dosage and minimizes radiation exposure to healthy tissues compared to lutetium-based treatments.

Research is ongoing to explore the isotope's unique properties, which could lead to advanced radiopharmaceuticals targeting various tumors with precision radiotherapy.

The starting material, gadolinium-160, is produced by Rosatom subsidiary Elektrokhimpribor, ensuring a reliable production chain. Rosatom's scientific division plays a critical role in nuclear medicine, producing isotopes for diagnostics and treatment, benefiting over 2.5 million patients annually worldwide.

This development aligns with Russia's focus on modernizing healthcare and improving access to cutting-edge medical technologies, showcasing Rosatom's commitment to advancing nuclear and non-nuclear innovations.